EGFR and lung carcinoma: For patients with EGFR-mutant lung cancer experienced better response to EGFR-TKI or chemotherapy as compared to those with EGFR wild-type one if the patients suffered from disease recurrence into advanced stage (31–34), this may partly explain the discrepancy in results between our research and prior studies.